Luspatercept for primary myelofibrosis

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 2 registered trials.

Why this status

  1. 22 Jan 2021: Trial registered, NCT04717414
  2. 25 Feb 2021: Trial started, NCT04717414

The trials

NCT04717414: An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions

State
Under way
Phase
Phase 3
People
313 taking part
Started
25 Feb 2021
Primary completion
26 May 2025
Arms
Experimental Arm: Luspatercept (ACE-536)
Results
Posted on the registry
  1. 22 Jan 2021: Trial registered
  2. 25 Feb 2021: Trial started
  3. 16 Jul 2026: Trial results posted

NCT07539779: Luspatercept in Preventing Poor Erythroid Engraftment for Hematological Malignancies With Moderate to Severe Myelofibrosis

State
Not started
Phase
Phase 2 and Phase 3
People
196 planned
Started
1 May 2026
Primary completion
1 Jan 2030
Arms
Luspatercept group
Results
None posted
  1. 20 Apr 2026: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.